Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of RHN-001 in Healthy Volunteers
NCT05847218Phase 1Completed
- Sponsor
- RH Nanopharmaceuticals
- Start
- Mar 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Amigesic in osteoarthritis (OA), rheumatoid arthritis (RA) and pain (4 cohorts), sponsored by RH Nanopharmaceuticals. Primary endpoints: Safety and tolerability profile of SAD of RHN-001 and Safety Endpoints of MAD of RHN-001. Started Mar 2023; status: completed.
02
Drugs
Amigesic
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)pain
Beyond the preview
Go deeper on NCT05847218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05847218.